K. Whelan

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

T. Whelan, C. Hudis, K. Gelmon, 2016, The New England journal of medicine.

A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.

E. Winer, T. Whelan, C. Hudis, 2016 .

Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.

T. Whelan, M. Brundage, J. Ingle, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase II study of cisplatin plus radiotherapy versus durvalumab plus radiotherapy followed by adjuvant durvalumab versus durvalumab plus radiotherapy followed by adjuvant tremelimumab and durvalumab in intermediate risk, HPV-positive, locoregionally advanced oropharyngeal squamous cell

J. Machiels, K. Sultanem, W. Parulekar, 2018, Annals of Oncology.